key: cord-0973184-8020k64a
authors: Harzallah, Inès; Debliquis, Agathe; Drénou, Bernard
title: Lupus anticoagulant is frequent in patients with Covid‐19
date: 2020-05-11
journal: J Thromb Haemost
DOI: 10.1111/jth.14867
sha: a5db533df5195a7afe4e008d15413db084b96eea
doc_id: 973184
cord_uid: 8020k64a

Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI)2. No lupus anticoagulant was detected in any of the patients.

Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. 

The authors declare that they have no conflicts of interest. 

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Viral infections and antiphospholipid antibodies